Celcuity reports Phase 3 VIKTORIA-1 data in PIK3CA-mutant breast cancer at ESMO

Celcuity announced Phase 3 VIKTORIA-1 data at ESMO Saturday in PIK3CA-mutant breast cancer, showing 59% ORR and 19.4-month DOR for the gedatolisib triplet versus 33% and 7.5 months for alpelisib plus fulvestrant.

Detected & updated continuously · Source: Nebula